140 related articles for article (PubMed ID: 16741154)
1. Gefitinib prevents bleomycin-induced lung fibrosis in mice.
Ishii Y; Fujimoto S; Fukuda T
Am J Respir Crit Care Med; 2006 Sep; 174(5):550-6. PubMed ID: 16741154
[TBL] [Abstract][Full Text] [Related]
2. Gefitinib attenuates murine pulmonary fibrosis induced by bleomycin.
Wang P; Tian Q; Liang ZX; Yang Z; Xu SF; Sun JP; Chen LA
Chin Med J (Engl); 2010 Aug; 123(16):2259-64. PubMed ID: 20819676
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis.
Suzuki H; Aoshiba K; Yokohori N; Nagai A
Cancer Res; 2003 Aug; 63(16):5054-9. PubMed ID: 12941834
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
[TBL] [Abstract][Full Text] [Related]
5. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
6. Antifibrotic effects of focal adhesion kinase inhibitor in bleomycin-induced pulmonary fibrosis in mice.
Kinoshita K; Aono Y; Azuma M; Kishi J; Takezaki A; Kishi M; Makino H; Okazaki H; Uehara H; Izumi K; Sone S; Nishioka Y
Am J Respir Cell Mol Biol; 2013 Oct; 49(4):536-43. PubMed ID: 23642017
[TBL] [Abstract][Full Text] [Related]
7. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
[TBL] [Abstract][Full Text] [Related]
8. Metformin attenuates gefitinib-induced exacerbation of pulmonary fibrosis by inhibition of TGF-β signaling pathway.
Li L; Huang W; Li K; Zhang K; Lin C; Han R; Lu C; Wang Y; Chen H; Sun F; He Y
Oncotarget; 2015 Dec; 6(41):43605-19. PubMed ID: 26497205
[TBL] [Abstract][Full Text] [Related]
9. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
[TBL] [Abstract][Full Text] [Related]
10. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
[TBL] [Abstract][Full Text] [Related]
11. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.
Wang W; Li Q; Takeuchi S; Yamada T; Koizumi H; Nakamura T; Matsumoto K; Mukaida N; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
Clin Cancer Res; 2012 Mar; 18(6):1663-71. PubMed ID: 22317763
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib, a Small-Molecule Kinase Inhibitor, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice.
Huang X; Wang W; Yuan H; Sun J; Li L; Wu X; Luo J; Gu Y
Tohoku J Exp Med; 2016 Aug; 239(4):251-61. PubMed ID: 27439438
[TBL] [Abstract][Full Text] [Related]
14. [Gefitinib inhibits α-smooth muscle actin expression in mice with bleomycin-induced lung fibrosis].
Li L; Li WF; Cai L; Yuan WF; Huang WJ
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Dec; 30(12):2675-8. PubMed ID: 21177177
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effect of emodin on bleomycin-induced pulmonary fibrosis in mice.
Chen XH; Sun RS; Hu JM; Mo ZY; Yang ZF; Jin GY; Guan WD; Zhong NS
Clin Exp Pharmacol Physiol; 2009 Feb; 36(2):146-53. PubMed ID: 18785980
[TBL] [Abstract][Full Text] [Related]
16. Role of epidermal growth factor inhibition in experimental pulmonary hypertension.
Dahal BK; Cornitescu T; Tretyn A; Pullamsetti SS; Kosanovic D; Dumitrascu R; Ghofrani HA; Weissmann N; Voswinckel R; Banat GA; Seeger W; Grimminger F; Schermuly RT
Am J Respir Crit Care Med; 2010 Jan; 181(2):158-67. PubMed ID: 19850946
[TBL] [Abstract][Full Text] [Related]
17. Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors.
Choi YJ; Rho JK; Jeon BS; Choi SJ; Park SC; Lee SS; Kim HR; Kim CH; Lee JC
Cancer Chemother Pharmacol; 2010 Jul; 66(2):381-8. PubMed ID: 19921194
[TBL] [Abstract][Full Text] [Related]
18. Targeting protease activated receptor-1 with P1pal-12 limits bleomycin-induced pulmonary fibrosis.
Lin C; Duitman J; Daalhuisen J; Ten Brink M; von der Thüsen J; van der Poll T; Borensztajn K; Spek CA
Thorax; 2014 Feb; 69(2):152-60. PubMed ID: 24029744
[TBL] [Abstract][Full Text] [Related]
19. Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells.
Amin DN; Bielenberg DR; Lifshits E; Heymach JV; Klagsbrun M
Microvasc Res; 2008 May; 76(1):15-22. PubMed ID: 18440031
[TBL] [Abstract][Full Text] [Related]
20. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
Okabe T; Okamoto I; Tsukioka S; Uchida J; Hatashita E; Yamada Y; Yoshida T; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
Clin Cancer Res; 2009 Feb; 15(3):907-13. PubMed ID: 19188161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
